We provide the latest news
from the world of economics and finance
(RTTNews) - Novartis AG (NVS) Thursday announced that the FDA has granted Breakthrough Therapy designation to Scemblix for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia or CML in chronic phase. This is the third Breakthrough Therapy designation assigned to Scemblix.
The designation is based on positive data from the Phase III ASC4FIRST study, in which Scemblix met both primary endpoints, compared to imatinib alone. In comparison with standard-of-care drugs, Scemblix demonstrated a favorable safety and tolerability profile.
Breakthrough Therapy designation is usually to a drug compound that targets a serious or life-threatening disease and demonstrates a potential substantial improvement over existing therapies.
Currently, shares are at $101.42, up 1.20 percent from the previous close of $100.21 on a volume of 176,838.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.